We represented Quest Diagnostics (NYSE: DGX) in its acquisition of intellectual property assets relating to MyPRS test from Signal Genetics (NASDAQ: SGNL). Myeloma Prognostic Risk Signature, or MyPRS, test analyzes the activity of genes to predict whether an individual is at high risk or low risk for early relapse. Knowing the risk of relapse helps to predict patient outcome.

Quest Diagnostics is the world’s leading provider of diagnostic information services that patients and doctors need to make better healthcare decisions.